We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MaxCyte Signs Strategic Platform License With LG Chem To Advance its Allogeneic CAR-T Programs
Product News

MaxCyte Signs Strategic Platform License With LG Chem To Advance its Allogeneic CAR-T Programs

MaxCyte Signs Strategic Platform License With LG Chem To Advance its Allogeneic CAR-T Programs
Product News

MaxCyte Signs Strategic Platform License With LG Chem To Advance its Allogeneic CAR-T Programs


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "MaxCyte Signs Strategic Platform License With LG Chem To Advance its Allogeneic CAR-T Programs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT) has announced the signing of a strategic platform license (SPL) with LG Chem Ltd.


Under the terms of the agreement, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.


Further accelerating its efforts for clinical development of global new drugs, LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeutic.[1] 


Doug Doerfler, President and CEO of MaxCyte, said: “We are thrilled to partner with the global multinational company LG Chem to support their CAR T programs for solid tumors. This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer.”


MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. LG CHEM is MaxCyte’s first SPL in Asia and 17th overall,  which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

Advertisement